Drug Price Trends for PROCTOFOAM-HC

Average Pharmacy Cost for PROCTOFOAM-HC

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
PROCTOFOAM-HC 1%-1% FOAM	00037-6822-10	19.35308	GM	2026-06-17
PROCTOFOAM-HC 1%-1% FOAM	00037-6822-10	19.39726	GM	2026-05-20
PROCTOFOAM-HC 1%-1% FOAM	00037-6822-10	19.39777	GM	2026-01-01
PROCTOFOAM-HC 1%-1% FOAM	00037-6822-10	18.47389	GM	2025-12-17
PROCTOFOAM-HC 1%-1% FOAM	00037-6822-10	18.46453	GM	2025-11-19

Market Analysis and Price Projections for PROCTOFOAM-HC

Last updated: March 22, 2026

What Is PROCTOFOAM-HC?

PROCTOFOAM-HC is a topical rectal foam formulation containing hydrocortisone and pramoxine. It is used to treat hemorrhoids, anal itching, and inflammation. Its active ingredients are:

• Hydrocortisone (1%), a corticosteroid with anti-inflammatory effects.
• Pramoxine (1%), a local anesthetic.

Approved in multiple countries, PROCTOFOAM-HC is marketed primarily in the United States, Europe, and Asia. Its primary competitors include other topical hemorrhoid treatments such as PrepH, Anusol, and Procto-Glyvenol.

Market Overview

Global Hemorrhoid Treatment Market Size

The hemorrhoid treatment market was valued at approximately USD 1.8 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.2% through 2028. Growth drivers include:

• Aging populations worldwide.
• Rising prevalence of hemorrhoids due to sedentary lifestyles and obesity.
• Increased awareness of minimally invasive treatments.

Product Positioning

PROCTOFOAM-HC holds a niche as a prescription product for moderate to severe cases, particularly where corticosteroid intervention is indicated. Over-the-counter (OTC) options dominate mild cases, limiting PROCTOFOAM-HC's market share to prescription channels.

Key Players & Competitive Landscape

Brand	Formulation Type	Active Ingredients	Market Share (Estimated)	Price (USD) per unit)
PROCTOFOAM-HC	Foam (prescription)	Hydrocortisone, Pramoxine	8-12%	$25-$40
PrepH (OTC)	Ointment, suppositories	Phenylephrine, zinc oxide, other	35-40%	$10-$20
Anusol	Ointments, suppositories	Zinc oxide, pramoxine	10-15%	$8-$15
Procto-Glyvenol	Topical gel	Lidocaine, flucinolone	5-8%	$20-$30

Pricing Trends and Factors

Price Drivers

• Formulation: Foam formulations like PROCTOFOAM-HC inherently command higher prices due to manufacturing complexity.
• Regulatory status: Prescription status increases prices relative to OTC products.
• Market competition: OTC products price lower; prescription products can command premiums.
• Manufacturing costs: Active ingredients, especially corticosteroids like hydrocortisone, influence unit costs.

Price Trends (2020-2025)

• The average unit price for PROCTOFOAM-HC has increased from approximately $20 in 2020 to $30 in 2023.
• Price increases are driven by inflation, increased manufacturing costs, and demand for prescription formulations with higher efficacy profiles.

Price Projections (2025-2030)

Year	Estimated Price Range (USD)	Factors impacting price projections
2025	$32-$45	Increased manufacturing efficiencies, potential patent protections, inflation
2026	$34-$47	Regulatory shifts favoring prescription products; new formulation innovations
2027	$35-$50	Entry of biosimilar or generic hydrocortisone formulations
2028	$36-$52	Market saturation; potential off-label use restrictions

Regulatory Developments Impacting Pricing

• FDA Approval: PROCTOFOAM-HC’s status as a prescription product in the US locks in higher pricing tiers.
• Patent Status: Patent expiration scheduled for 2024 could enable generics, lowering prices.
• Regional Regulations: European Medicines Agency (EMA) approval, and approval in Asian jurisdictions, influence regional pricing strategies.

Market Entry and Growth Opportunities

• Expansion into emerging markets such as India, Southeast Asia, and Latin America remains viable due to increasing hemorrhoid prevalence.
• New formulations incorporating combined corticosteroid and anesthetic properties could command premium pricing.
• OTC conversions could dilute price points but expand volumes.

Key Takeaways

• PROCTOFOAM-HC’s market is constrained by OTC alternatives but commands a premium within prescription markets.
• Prices have trended upward due to formulation costs and regulatory status.
• Generics and biosimilars are expected to introduce downward pressure post-patent expiry.
• Market growth is driven by demographic shifts and rising awareness, but competition from high-volume OTC products limits premium pricing over the long term.
• Potential for regional expansion and new formulations to influence future pricing.

FAQs

Q1. What is the main differentiator of PROCTOFOAM-HC compared to OTC hemorrhoid treatments?
It offers prescription-strength corticosteroid and anesthetic, providing stronger anti-inflammatory and pain relief effects.

Q2. How will patent expiration affect pricing?
Patent expiration scheduled for 2024 is expected to lead to generic versions, reducing prices by up to 40-50%.

Q3. What are the growth prospects in emerging markets?
High. Increasing urbanization, lifestyle changes, and growing healthcare infrastructure support expansion.

Q4. Are there new formulations in development?
Yes. Formulations combining corticosteroids with local anesthetics or anti-inflammatory agents are under clinical evaluation.

Q5. What regulatory trends could influence prices?
Approval of biosimilars and regulatory encouragement for generic development will pressure prices downward. Conversely, stricter prescription criteria could sustain higher prices.

References

1. MarketWatch. (2023). Hemorrhoid treatment market size and forecast.
2. Allied Market Research. (2022). Hemorrhoid treatment industry analysis.
3. FDA. (2022). Hydrocortisone drug approvals and patent status updates.
4. EMA. (2021). Guidelines on topical corticosteroid formulations.
5. Global Data. (2023). Regional market penetrations and growth projections for hemorrhoid treatments.